European Leukemia Trial Registry
Trial: AML SORAML SAL

More Details
Title Sorafenib in adult Patients with acute myeloid leukemia ≤ 60 years of age
Scientific Title A double-blind, placebo-controlled, randomized, multi-center phase-II trial to assess the efficacy of Sorafenib added to standard primary therapy in patients with newly diagnosed AML ≤60 years of age
Short Title AML SORAML SAL
Trialgroup SAL
Type of Trial multicentric, randomized
Disease Acute myeloid leukemia(AML) AML all subtypes without FAB M3
Age <= 60 years
Status No longer recruiting
Start of Recruitment 27.03.2009
Leader Ehninger, Prof. Dr. med., Gerhard
Contactperson

Study coordinator
Röllig, PD Dr., Christoph
Tel: +49 (0)351 458 3775
Email: Christoph.Roellig@uniklinikum-dresden.de

Study Centre
Lehmann, Gina
Tel: +49 (0)351 458 7172
Fax: +49 (0)351 458 4367
Email: gina.lehmann@uniklinikum-dresden.de

Centre of Trial SAL-Studienzentrale, Universitätsklinikum Carl Gustav Carus, Dresden
Shortprotocol Shortprotocol
Diagnostics

Central diagnostics
Hämatologisches Labor, Universitätsklinikum Dresden

Remark www.sal-aml.org
created 30.06.2009 Roswitha Kotthoff
changed 30.07.2018 Martina Wolkenfeld
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org